Bladder News and Research

RSS

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

19 Apr 2010

EAU honours urological experts at 25th Anniversary Congress

On 16 April 2010 the European Association of Urology opened its 25th Anniversary Congress. During the ceremony, several urological experts were honoured with awards for the outstanding work they did for the urological community. EAU Secretary General Per-Anders Abrahamsson handed them out.

17 Apr 2010

Updated clinical guidelines presented at EAU Anniversary Congress

A number of updated guidelines are presented at the Anniversary Congress of the European Association of Urology (EAU) held in Barcelona, from 16 through 20 April. The abridged versions - Pocket Guidelines - which are based on the extended text documents will also be available in Barcelona to all EAU members and press.

17 Apr 2010

SNM continues to stress the need for Congress to implement long-term fix

On April 16, the President signed a bill granting temporary relief from looming cuts to Medicare reimbursement rates. Although a positive step, the medical community-along with millions of patients-continues to face significant threats to medical coverage for critical diagnostic imaging tests and therapeutics.

17 Apr 2010

Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009

Tikcro Technologies Ltd. today reported results for the fourth quarter and year ended December 31, 2009.

17 Apr 2010

MinuteClinic helps patients take control of allergies with treatment services seven days a week

As trees blossom and shed their pollen and grasses and weeds germinate in yards and fields across America, allergy sufferers are retreating indoors with seemingly no relief in sight. MinuteClinic, the walk-in medical clinic inside select CVS/pharmacy stores, can help patients breathe easier and take control of their allergies this spring with treatment services available seven days a week, including weekday evening hours.

16 Apr 2010

University Hospital of Zurich treats cancer patients with Varian Medical Systems' TrueBeam system

The University Hospital of Zurich has become the first medical center in the world to commence treating cancer patients with the revolutionary TrueBeam system from Varian Medical Systems, a new platform for image-guided radiotherapy and radiosurgery that was designed from the ground up to treat a moving target with unprecedented speed and precision.

16 Apr 2010

Trans-urethral prostate hyperthermia treatment offers 100% response rate

According the Dr. Friedrich Douwes, Medical Director of St. George Hospital in Bad Aibling, Germany, president of the German Oncological Society and the author of several hundred scientific articles and books, trans-urethral prostate hyperthermia has a 100% initial response rate.

16 Apr 2010

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.

15 Apr 2010

Early, accurate detection of superficial bladder cancer with Olympus PDD

With Olympus photodynamic diagnosis (PDD), superficial bladder cancer can be detected earlier, easier and more accurately. Bladder cancer is diagnosed by cystoscopy, the endoscopic introduction of a light source through the urethra (transurethral) into the bladder. The imaging technology PDD uses blue light to increase the contrast between tumour tissue (red) and healthy tissue (blue).

From Evident Corporation - Life Sciences 15 Apr 2010

UA Superfund Research Program to study contaminated dust, water and health issues

Metal-laden dust and contaminated water, and their health effects, will be the focus of multiple projects for the University of Arizona's Superfund Research Program during the next five years. The National Institutes of Environmental Health Sciences recently notified UA that the Superfund Research Program, funded since 1989, will receive an additional $14 million in grant funding through 2015 to conduct the research.

15 Apr 2010

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Restrictions should be placed on the use of Ginkgo biloba - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes. The article appears in ACS' monthly Journal of Natural Products.

15 Apr 2010

Over 12,000 participants already registered for 25th Anniversary EAU Congress

The upcoming 25th Anniversary EAU Congress in Barcelona from April 16 to 20 promises to be one of the EAU's biggest meetings in recent years with around 12,100 participants already registered to attend the annual urological event.

12 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

Researchers develop new mouse model of VUR to study chronic kidney disease in children

Kidney damage associated with chronic reflux is the fourth leading cause of chronic kidney disease and is the most common cause of severe hypertension in children. Doctors and researchers at Nationwide Children's Hospital have developed a new mouse model of vesicoureteral reflux, a common childhood condition that can lead to chronic kidney disease in children.

7 Apr 2010

Investment report featuring Antares Pharma from BeaconEquity.com

BeaconEquity.com announces an investment report featuring medical instruments company Antares Pharma Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

7 Apr 2010

New study to compare Botox against oral medications for urge incontinence in women

A new study is underway at Loyola University Health System to compare botulinum toxin A or Botox® versus common oral medications for urge incontinence in women. Urge incontinence is urinary incontinence with a strong or sudden need to urinate. Millions of women suffer in silence each day from this condition.

6 Apr 2010

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the fourth quarter and fiscal year ended December 31, 2009.

5 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

NAFC supports PMAA of Uromedica's ACT device for SUI, speaks to FDA

On March 24, Nancy Muller, executive director of The National Association For Continence (NAFC), spoke to the Food and Drug Administration (FDA), in support of a Premarket Approval Application (PMAA) of Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device to approve its usage in the U.S. The ACT is designed to treat female stress urinary incontinence (SUI).

2 Apr 2010

Bladder News and Research

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

EAU honours urological experts at 25th Anniversary Congress

Updated clinical guidelines presented at EAU Anniversary Congress

SNM continues to stress the need for Congress to implement long-term fix

Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009

MinuteClinic helps patients take control of allergies with treatment services seven days a week

University Hospital of Zurich treats cancer patients with Varian Medical Systems' TrueBeam system

Trans-urethral prostate hyperthermia treatment offers 100% response rate

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

Early, accurate detection of superficial bladder cancer with Olympus PDD

UA Superfund Research Program to study contaminated dust, water and health issues

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Over 12,000 participants already registered for 25th Anniversary EAU Congress

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Researchers develop new mouse model of VUR to study chronic kidney disease in children

Investment report featuring Antares Pharma from BeaconEquity.com

New study to compare Botox against oral medications for urge incontinence in women

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

Cancer research at Georgia Tech: Report

NAFC supports PMAA of Uromedica's ACT device for SUI, speaks to FDA

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News